Anti-CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionB-lymphocyte antigen CD19 modulators

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLymphomaPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesThe First Affiliated Hospital Of Nanchang University

China Registration ClassN/A

Develop Information

Active CompaniesThe First Affiliated Hospital Of Nanchang University

Inactive CompaniesN/A

Active IndicationsLymphoma

Inactive IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Other Information

ATC CodeN/A